Stoke Therapeutics, Inc. STOK
24.80
(0.49)
(1.94%)
as of 25 Sep
- Market cap
- $1.6B
- P/E
- 0.0×
Follow STOK
| Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
— | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
— | — | — | — | — | 28.50 | 29.36 | 16.30 | 10.19 |
P/FCF ratio |
— | — | — | — | — | 0.00 | 0.00 | 0.00 | 41.85 |
P/Operating CF |
— | — | — | — | — | (15.80) | (12.49) | (25.69) | (61.72) |
P/B ratio |
— | — | — | — | — | 1.91 | 1.62 | 2.60 | 5.33 |
Price to Tangible BV |
— | — | — | — | — | 1.91 | 1.62 | 2.60 | 5.33 |
EV/Sales |
— | — | — | — | — | 9.99 | 6.43 | 10.36 | 8.65 |
EV/EBITDA |
— | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
— | — | — | — | — | (3.89) | (0.70) | (4.36) | 34.99 |
EV/FCF |
— | — | — | — | — | (3.46) | (0.68) | (4.35) | 35.51 |
Quick Ratio |
0.48 | 42.80 | 54.32 | 25.15 | 12.83 | 7.33 | 6.54 | 5.48 | 5.06 |
Current Ratio |
0.51 | 43.03 | 55.12 | 25.73 | 13.37 | 7.77 | 6.99 | 5.81 | 5.28 |
Net Debt/EBITDA |
(0.22) | 8.39 | 6.32 | 5.51 | 2.59 | 2.23 | 1.79 | 2.15 | 14.29 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
(2.32) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.05 | 0.04 | 0.15 | 0.53 |
Operating CF/Net income |
0.97 | 0.88 | 0.96 | 0.81 | 0.78 | 0.32 | 0.77 | 0.98 | (6.62) |
Capex/Depreciation |
0.00 | (4.32) | (3.63) | (1.18) | (1.07) | (2.97) | (0.75) | (0.38) | (1.05) |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| (10.71%) | (24.13%) | (19.62%) | (20.47%) | (34.06%) | (50.20%) | (60.80%) | (45.80%) | (2.37%) | |
| (10.11%) | (23.29%) | (19.22%) | (19.84%) | (31.97%) | (40.84%) | (43.23%) | (35.60%) | (2.00%) | |
ROIC |
0.00% | 0.00% | (1,139.44%) | 0.00% | 0.00% | 0.00% | 0.00% | (525.92%) | (19.12%) |
Return on Tangible Assets |
417.27% | (11.94%) | (14.40%) | (18.32%) | (39.68%) | (46.08%) | (55.01%) | (45.26%) | (2.74%) |
Average Days of Receivables |
— | 0.00 | 0.00 | 0.00 | 0.00 | 17.30 | 2.66 | 23.64 | 15.65 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 627.46% | 936.57% | 243.83% | 74.79% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 313.78% | 470.64% | 133.48% | 36.38% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 184.23% | 287.67% | 75.15% | 17.48% |
Graham Net Nets |
— | — | — | — | — | 0.49 | 0.57 | 0.32 | 0.13 |
Graham Number |
— | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
— | — | — | — | — | (28.60%) | (40.44%) | (15.23%) | (0.32%) |
Free Cash Flow Yield |
— | — | — | — | — | (10.13%) | (32.07%) | (14.61%) | 2.39% |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.32 | 0.20 | 0.68 | 3.11 |
Operating CF per Share |
(0.16) | (15.46) | (1.73) | (1.26) | (1.82) | (0.82) | (1.84) | (1.61) | 0.77 |
Capex per Share |
0.00 | (1.30) | (0.09) | (0.03) | (0.03) | (0.10) | (0.04) | 0.00 | (0.01) |
Free Cash Flow per Share |
(0.16) | (16.76) | (1.82) | (1.29) | (1.85) | (0.92) | (1.88) | (1.61) | 0.76 |
Cash per Share |
0.06 | 148.60 | 12.38 | 8.58 | 5.98 | 5.90 | 4.58 | 4.02 | 4.82 |
Shareholders Equity per Share |
(0.04) | 148.13 | 12.49 | 8.54 | 5.93 | 4.75 | 3.63 | 4.24 | 5.95 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(0.04) | 148.13 | 12.49 | 8.54 | 5.93 | 4.75 | 3.63 | 4.24 | 5.95 |
Free Cash Flow |
(5.38) | (11.89) | (32.69) | (43.27) | (68.11) | (35.83) | (82.68) | (87.05) | 44.92 |
Working Capital |
(1.80) | 103.68 | 221.93 | 282.51 | 212.08 | 212.68 | 184.52 | 192.70 | 247.83 |
Capital Expenditures |
(0.11) | (0.92) | (1.63) | (1.05) | (1.20) | (3.96) | (1.62) | (0.20) | (0.67) |
Net Current Asset Value |
(1.82) | 103.67 | 221.71 | 282.08 | 208.13 | 172.85 | 146.56 | 190.22 | 239.72 |
EV/EBIT |
— | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.32 | 0.18 | 0.01 | 0.00 |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (814.73%) | (1,192.47%) | (243.42%) | (3.73%) |
Price to Operating Income |
— | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | |||||||||
Depreciation/Fixed assets |
0.24 | 0.18 | 0.18 | 0.33 | 0.27 | 0.20 | 0.37 | 0.14 | 0.20 |
Cash ROIC |
(167.10%) | (5.78%) | (7.51%) | (7.83%) | (16.24%) | (9.30%) | (24.07%) | (20.35%) | 6.66% |
Accounts Receivable Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 34.46 | 26.93 | 30.06 | 35.90 |
Accounts Payable Turnover |
0.19 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
455.44 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Average Receivables |
— | 0.24 | 0.24 | 0.14 | 0.07 | 0.36 | 0.33 | 1.22 | 5.14 |
Average Payables |
0.61 | 0.61 | 0.91 | 1.12 | 1.94 | 1.58 | 1.23 | 2.10 | 3.72 |
Average Assets |
54.99 | 53.77 | 168.14 | 263.34 | 268.40 | 247.47 | 242.20 | 249.95 | 344.99 |
Average Common Equity |
51.87 | 51.88 | 164.75 | 255.25 | 251.93 | 201.31 | 172.21 | 194.29 | 290.74 |
Columns are period end dates